healthSELLAS Reports Survival Benefit in Phase 3 Leukemia TrialSELLAS Life Sciences said its Phase 3 REGAL trial of the experimental cancer vaccine galinpepimut-S met its primary overall-survival endpoint in patients with acute myeloid leukemia, reporting median survival of 24... Coverage Mix 5 source articles Left 0% Centre 100% Right 0% 3 hours agohealth